Eisai R&d Management Co., Ltd.

Novartis Ag

Arrowhead Pharmaceuticals, Inc.

Arrowhead Research Corporation

Ping Zhu

Markus Warmuth

Wenlai Zhou

Gregory Hinkle

Stuart Milstein

Satyanarayana Kuchimanchi

Tracy Stage Zimmermann

Peter G Smith

Silvia Buonamici

Lihua Yu

Michael W Seiler

James Palacino

Ermira Pazolli

Nathan Elliott Fishkin

Thiwanka Samarakoon

Dominic J Reynolds

Andrew Cook

Sudeep Prajapati

Xiang Liu

Shelby Ellery

Megan Sheehan

Manav Korpal

Nicholas Calandra

Yonghong Xiao

Zhenhua Wu

Mark G Bock

John JianShi Wang

Guo Zhu Zheng

Ming-Hong Hao

Susanta Samajdar

Yoshiharu Mizui

Kian Huat Lim

Eunice Sun Park

Jacob D Feala

Shouyong Peng

Xiaoling Puyang

Marco Peter Fekkes

Vijay Kumar Nyavanandi

Juan C Almagro

Giordano Caponigro

Peter Gerard Smith

Vesselina Cooke

Scott Delach

Jinyun Chen

Joshua Korn

Daniel Aird

Laura Corson

Peter Fekkes

Ryan Henry

Evan Barry

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Splicing modulator antibody-drug conjugates and methods of use

The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.

Organic compositions to treat HSF1-related diseases

Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.

Anti-BCMA antibody-drug conjugates and methods of use

This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.

Methods of using splicing modulators

Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.

Splice variants associated with neomorphic SF3B1 mutants

The present disclosure provides pharmaceutical combinations comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors. Also provided are methods of treating cancer comprising administering a therapeutically effective amount of at least one spliceosome modulator and a therapeutically effective amount of at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors.

Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-&#x3b1; protein.

Tetrasubstituted alkene compounds and their use

Compositions and methods are provided for diagnosis, prognosis and treatment of AR-related diseases, such as prostate diseases, such as prostate cancer, breast cancer, and many other diseases. In particular, a novel and clinically relevant mutation at position 877 of the androgen receptor (AR) has been identified. Drug sensitivity can be predicted and therapeutic regimens can be planned on the basis of the presence or absence of this mutation. Polypeptides comprising, antibodies to, and polynucleotides encoding the mutant AR can be used to identity novel treatments. A double mutation in AR at positions 742 and 878 is also shown to be useful for patient stratification.

Androgen receptor mutation

Growing community of inventors

Cambridge, MA, United States of America

Ping Zhu